In the context of infectious diseases (e.g., COVID-19, influenza, pneumonia), there might also be opportunities to improve the immunological status while acting on the background biology of aging through pharmacological interventions (e.g., low-dose mammalian Target of Rapamycin [mTOR] inhibitors) (25). The gene discussed is MTOR; the disease is COVID-19.